Skip to main content
. 2021 Nov 1;10(10):15. doi: 10.1167/tvst.10.10.15

Figure 4.

Figure 4.

The complex puzzle of therapeutic development for outer retinal cell therapies. As cell therapies transition from phase T1 to phase T2 studies and beyond, several interconnected factors related to donor cell manufacturing and preclinical testing must be addressed.